HTDS down to 0.0074

HTDS issued a press release today:

Hard to Treat Diseases (HTDS.PK) Business Summary Update

SHENZHEN, China, Dec. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com is using this opportunity to update its followers on the development of several previously announced events, which remain unresolved and or pending. These are Slavica Biochem's move into the Revenue Mode, Slavica's research expansion and pending EU Stem Cell Bank merger, HTDS' Africa Opportunity, HTDS' Pink Sheets "skull and bones" rankings, and the expected Q4 results...

Nothing really bad but nothing really specific here either. Investors, including myself would like to see some cold hard numbers and facts from HTDS. What is their revenue? Where's the Q3? Who is this EU company?

I still like HTDS but we all need to start seeing some more substantial news and info from them. HTDS may stay under a penny for a while and go down even more without material news from them.